Role of HOTTIP and HOXA9 in blood stem cells and leukemia
Official title: Role of HOTTIP/beta-catenin-HOXA9/PRMT1 axis in hematopoietic and leukemic stem cells
Funded at Pennsylvania State Univ Hershey Med Ctr · NIH-11411130 · Data updated 2026-11-12
This grant looks at how a specific gene network drives the self-renewal of blood stem cells and leukemia stem cells, with the hope of finding targeted ways to treat AML.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pennsylvania State Univ Hershey Med Ctr NIH-funded |
| Lab location | 1 site (Hershey, United States) |
| Project start | July 1, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $303,207 |
| NIH project number | 5R01CA264932-05 |
| Project ID | NIH-11411130 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include adults with acute myeloid leukemia or at-risk individuals contributing samples for research; genetic and cellular analyses may involve adult patients.
✕Less likely to help
Patients without access to AML-directed therapies or those not contributing samples may see no direct benefit.
What this research studies
The research focuses on how the HOTTIP RNA, beta-catenin, HOXA9, and PRMT1 interact to regulate self-renewal in normal hematopoietic stem cells and leukemia stem cells. The team will study these molecular pathways in adult human samples, animal models, and cellular systems to understand why leukemia stem cells persist and how they differ from healthy stem cells. By exploring how this network sustains malignant behavior, the project aims to identify potential targets for therapies that spare normal blood formation. Findings could guide future development of treatments that specifically attack leukemia-initiating cells. The work is designed to fill critical gaps in how transcriptional and signaling programs promote AML maintenance at the stem cell level.
Why it matters
Potential benefit: If successful, this work could lead to new therapeutic strategies that target leukemia stem cells while preserving normal blood-forming cells.
How similar studies have gone: Previous research links Wnt signaling and HOXA9 to AML maintenance; this study builds on those findings with a focus on lncRNA-mediated regulation.
Where this research is happening
-
Pennsylvania State Univ Hershey Med Ctr
Hershey, United States Active
Researchers
- Principal investigator: Huang, Suming — Pennsylvania State Univ Hershey Med Ctr
- Study coordinator: Huang, Suming
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.